Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Telemedicine Outreach for Post Traumatic Stress in CBOCs
Telemedicine Outreach for Post Traumatic Stress in CBOCs
Status: Enrolling
Updated:  12/31/1969
Central Arkansas Veterans Healthcare System (North Little Rock)
mi
from
North Little Rock, AR
Telemedicine Outreach for Post Traumatic Stress in CBOCs
Telemedicine Outreach for Post Traumatic Stress in CBOCs
Status: Enrolling
Updated: 12/31/1969
Central Arkansas Veterans Healthcare System (North Little Rock)
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Cognitive Training to Enhance VA Work Program Outcomes
Cognitive Training to Enhance VA Work Program Outcomes
Status: Enrolling
Updated:  12/31/1969
VA Connecticut Healthcare System
mi
from
West Haven, CT
Cognitive Training to Enhance VA Work Program Outcomes
Cognitive Training to Enhance VA Work Program Outcomes
Status: Enrolling
Updated: 12/31/1969
VA Connecticut Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
Eskenazi Hospital
mi
from
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
Eskenazi Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital
mi
from
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated:  12/31/1969
University Hospital
mi
from
Indianapolis, IN
Pharmacological Management of Delirium
Pharmacological Management of Delirium
Status: Enrolling
Updated: 12/31/1969
University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Measures to Lower the Stress Response in Pediatric Cardiac Surgery
Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl (LDF), Low Dose Fentanyl Plus Dexmedetomidine (LDF + Dex) and High Dose Fentanyl (HDF).
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Measures to Lower the Stress Response in Pediatric Cardiac Surgery
Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl (LDF), Low Dose Fentanyl Plus Dexmedetomidine (LDF + Dex) and High Dose Fentanyl (HDF).
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
National Children s Health Study
Vanguard Phase of the National Children s Study
Status: Enrolling
Updated:  12/31/1969
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
mi
from
Bethesda, MD
National Children s Health Study
Vanguard Phase of the National Children s Study
Status: Enrolling
Updated: 12/31/1969
National Institute of Child Health and Human Development (NICHD), 9000 Rockville
mi
from
Bethesda, MD
Click here to add this to my saved trials
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
Use of Dexmedetomidine for Emergence Delirium in Children Undergoing General Anesthesia for Endovascular Interventional Neuroradiologic Procedures
Status: Enrolling
Updated:  12/31/1969
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
Use of Dexmedetomidine for Emergence Delirium in Children Undergoing General Anesthesia for Endovascular Interventional Neuroradiologic Procedures
Status: Enrolling
Updated: 12/31/1969
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Shanti Clinical Trials
mi
from
Colton, CA
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Shanti Clinical Trials
mi
from
Colton, CA
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Center for Healing the Human Spirit
mi
from
Tarzana, CA
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Center for Healing the Human Spirit
mi
from
Tarzana, CA
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Brain Resource Center
mi
from
Englewood Cliffs, NJ
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Brain Resource Center
mi
from
Englewood Cliffs, NJ
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Brain Resource Center
mi
from
New York, NY
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Brain Resource Center
mi
from
New York, NY
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Brain Dynamics Centre
mi
from
Westmead,
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Brain Dynamics Centre
mi
from
Westmead,
Click here to add this to my saved trials
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated:  12/31/1969
Skyland Behavioral Health Associates , P.A.
mi
from
Asheville, NC
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.
Status: Enrolling
Updated: 12/31/1969
Skyland Behavioral Health Associates , P.A.
mi
from
Asheville, NC
Click here to add this to my saved trials
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Comprehensive Disease Management Program for Medically-Complex Substance Users
A Comprehensive Disease Management Program for Medically-Complex Substance Users
Status: Enrolling
Updated:  12/31/1969
East Baltimore Medical Center
mi
from
Baltimore, MD
A Comprehensive Disease Management Program for Medically-Complex Substance Users
A Comprehensive Disease Management Program for Medically-Complex Substance Users
Status: Enrolling
Updated: 12/31/1969
East Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Pharmacotherapy of Pervasive Developmental Disorders
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children, Christian Sarkine Autism Treatment Center
mi
from
Indianapolis, IN
Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders
Pharmacotherapy of Pervasive Developmental Disorders
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children, Christian Sarkine Autism Treatment Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Columbia University, 622 W. 168th St.
mi
from
New York, NY
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Columbia University, 622 W. 168th St.
mi
from
New York, NY
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study
Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Neurobehavioral Center
mi
from
Columbia, MD
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Neurobehavioral Center
mi
from
Columbia, MD
Click here to add this to my saved trials
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Peri-Anesthetic Imaging of Cognitive Dysfunction
Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates
mi
from
Tucson, AZ
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates
mi
from
Tucson, AZ
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group
mi
from
Bentonville, AR
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group
mi
from
Bentonville, AR
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Aurora, CO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Aurora, CO
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers, Site #191
mi
from
Boulder, CO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers, Site #191
mi
from
Boulder, CO
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Integrated Community Oncology Network-St. Vincent's
mi
from
Jacksonville, FL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Integrated Community Oncology Network-St. Vincent's
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Integrated Community Oncology Network-Southside
mi
from
Jacksonville, FL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Integrated Community Oncology Network-Southside
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Integrated Community Oncology Network
mi
from
Orange Park, FL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Integrated Community Oncology Network
mi
from
Orange Park, FL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Carle Physician Group
mi
from
Danville, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Carle Physician Group
mi
from
Danville, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Crossroads Cancer Center
mi
from
Effingham, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Crossroads Cancer Center
mi
from
Effingham, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Carle Foundation Physician Services
mi
from
Mattoon, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Carle Foundation Physician Services
mi
from
Mattoon, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Carle Cancer Center
mi
from
Urbana, IL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Baptist Hospital East
mi
from
Louisville, KY
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Baptist Hospital East
mi
from
Louisville, KY
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Harry and Jeanette Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Harry and Jeanette Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Cancer & Hematology Center of Western Michigan
mi
from
Grand Rapids, MI
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Cancer & Hematology Center of Western Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota CCOP-Unity Hospital
mi
from
Fridley, MN
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota CCOP-Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota CCOP-St. Johns
mi
from
Maplewood, MN
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota CCOP-St. Johns
mi
from
Maplewood, MN
Click here to add this to my saved trials
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated:  12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Status: Enrolling
Updated: 12/31/1969
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials